03:45 AM EST, 11/04/2026 (MT Newswires) -- Bayer (BAYN.F) secured approval in China for sevabertinib as a first-line treatment for advanced HER2-mutant non-small cell lung cancer, according to a Wednesday release. The German life science company said the National Medical Products Administration of China's decision followed a breakthrough therapy designation for the drug from the country's Center for Drug Evaluation. Sevabertinib already has approval for the same indication in the US and Japan. The latest decision was based on the results of the ongoing phase 1/2 Soho-01 trial, which assesses the safety and efficacy of the medication in the approved indication.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.